SICOR Biotech, a Global Company

Sicor Biotech sees the future for Lithuanian companies in the global context of high technologies. To be competitive, a companies need to attract investments and take part in large global projects.

Export and Foreign Markets

Sicor Biotech is actively increasing its exports and entering new markets. Sicor Biotech exports more then 80% of sales value of biotech products produced at our high value added company. We believe that the investments spent for our plant development project shall pay off with a twofold increase in the amount of produced drug products ad their export as soon as in 2012.
Currently drug products developed by biotechnologists at Sicor Biotech are marketed in over thirty countries.
Sicor Biotech UAB has been four times awarded the Lithuanian Exporter of the Year title by the Lithuanian Confederation of Industrialists.

An International Venture

Sicor Biotech is a member of Teva Corporation.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva is among the top 15 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.
With more than a century of experience in the healthcare industry, the Company enjoys a firmly established international presence, operating through a carefully tailored network of worldwide subsidiaries. Headquartered in Israel, above 80% of Teva's sales, which totalled US$13.9 billion in 2009, are in North America and Europe. Teva has over 35,000 employees worldwide and production facilities in Israel, North America, Europe and Latin America.

Teva Drug products for Patients in the Region

In 2006 Baltic Teva and IVAX representative offices were incorporated into Sicor Biotech, one of the largest Lithuanian biotech company This made it possible to expand the supply of drug products by Teva into the Baltics and other Eastern- and Middle-European countries. The company representatives distribute the drug products produced at Teva's European, Northern American, and Middle Eastern plants to Polish, Czech, Slovakian as well as Russian, Byelorussian, Kazakh, and other CIS markets.  
Also, Sicor Biotech has obtained a wholesale medicine trade license in 2006, which gave the company the right to supply drug products to Lithuanian market..